Reparixin for myelofibrosis patients who can’t use JAK inhibitors
Part of Blood & lymphatic clinical trials.
This Phase 2 study tests reparixin, a drug aimed at reducing problems caused by myelofibrosis (bone marrow scarring). It focuses on people who have intermediate-2 or higher risk myelofibrosis and either didn’t respond to JAK inhibitor treatment or can’t tolerate it, to see if symptoms and disease markers improve.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and are able and willing to sign the consent form.
- You have confirmed primary myelofibrosis or certain post-treatment myelofibrosis (post-ET or post-PV), with intermediate-2 or higher risk disease.
- Your daily functioning is good enough for study care (ECOG score 0–2).
- You must be willing to do a bone marrow biopsy for screening (or provide one done within the last 90 days).
- You have tried JAK inhibitor treatment (or couldn’t use it) and it wasn’t working well enough or caused side effects that stopped you from continuing.
- Your organs and blood counts are sufficient (specific lab thresholds) and you have a life expectancy of at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called revumenib, which is being studied for people with myelofibrosis. Revumenib may help slow the disease and improve symptoms. The study has two parts: one for people who have already tried a JAK inhibitor, and one for those currently on a JAK inhibitor but still have active disease.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This study tests a new drug called LY5830966 for people with myelofibrosis whose disease has not responded to or has returned after treatment with a type I JAK2 inhibitor. The drug aims to help reduce symptoms and improve outcomes.
This trial tests a combination of two medications, ropeginterferon alfa-2b and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough or has grown back while on ruxolitinib. The goal is to see if adding the newer drug can improve outcomes.
This Phase 2 trial tests whether elritercept, given alone or together with ruxolitinib, can improve symptoms and disease control in adults with myelofibrosis. It may help people who have anemia and either cannot tolerate, can’t get enough benefit from, or are already using ruxolitinib.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
Hear when a new Myelofibrosis (PMF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.